Goldman Sachs Cuts Price Target, Highlights Apple Risks

Goldman Sachs made notable moves in its analyst coverage on Tuesday, including a price target cut and a reiteration of a buy rating for Apple, while also shedding light on a clinical-stage biotech firm.

The investment bank lowered its price target on a stock to $14 from $18, according to CNBC's Jim Cramer. The specific stock was not named in the snippet, but the adjustment reflects a cautious outlook amid market volatility. Read more on CNBC.

Separately, Goldman Sachs reiterated its buy rating on Apple, but warned that the company's App Store revenue could act as an "overhang" on the stock. This suggests that regulatory pressures or slowing growth in the App Store may weigh on Apple's near-term performance. The bank remains bullish on the tech giant overall, however. Read more on CNBC.

In the same coverage, Goldman Sachs highlighted ANRO, a clinical-stage biotech company that uses a proprietary machine learning platform to develop precision medicines for neuropsychiatric disorders. While the bank's stance on ANRO was not explicitly stated, the mention underscores growing interest in AI-driven drug discovery.

Key Takeaways

1. Goldman Sachs lowered a price target to $14 from $18, signaling caution on a specific stock.
2. The bank reiterated Apple as a buy but flagged App Store revenue as a potential overhang.
3. ANRO, a biotech using machine learning for neuropsychiatric treatments, was also noted in Goldman's coverage.